JPH08506796A - ペプチドグリカン単量体（ｐｇｍ），そのｎ−アシル誘導体及びその金属錯体の、生体における免疫抑制状態及び肝抑制状態を補正するための薬剤調製への使用 - Google Patents

ペプチドグリカン単量体（ｐｇｍ），そのｎ−アシル誘導体及びその金属錯体の、生体における免疫抑制状態及び肝抑制状態を補正するための薬剤調製への使用

Info

Publication number
JPH08506796A
JPH08506796A JP5504098A JP50409893A JPH08506796A JP H08506796 A JPH08506796 A JP H08506796A JP 5504098 A JP5504098 A JP 5504098A JP 50409893 A JP50409893 A JP 50409893A JP H08506796 A JPH08506796 A JP H08506796A
Authority
JP
Japan
Prior art keywords
pgm
state
liver
carboxylic acid
acid group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5504098A
Other languages
English (en)
Japanese (ja)
Inventor
ラドシェヴィッチ−スタシッチ，ビセルカ
シュシュコヴィッチ，ボジダール
ナウムスキ，ラドミーラ
ルカヴィーナ，ダニイェル
Original Assignee
プリヴァ ハンデルス ゲゼルシャフト ミット ベシュレンクテル ハフツング
プリヴァ ファルマツェウツカ，ケミィスカ，プレフラムベーナ イ コズメティチュカ インダストリヤ，ス プ．オ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリヴァ ハンデルス ゲゼルシャフト ミット ベシュレンクテル ハフツング, プリヴァ ファルマツェウツカ，ケミィスカ，プレフラムベーナ イ コズメティチュカ インダストリヤ，ス プ．オ． filed Critical プリヴァ ハンデルス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JPH08506796A publication Critical patent/JPH08506796A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP5504098A 1991-08-15 1992-08-13 ペプチドグリカン単量体（ｐｇｍ），そのｎ−アシル誘導体及びその金属錯体の、生体における免疫抑制状態及び肝抑制状態を補正するための薬剤調製への使用 Pending JPH08506796A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
YU141291 1991-08-15
PCT/EP1992/001859 WO1993003746A1 (fr) 1991-08-15 1992-08-13 Preparation de medicaments contenant le monomere de peptidoglycane ou ses derives

Publications (1)

Publication Number Publication Date
JPH08506796A true JPH08506796A (ja) 1996-07-23

Family

ID=25554075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5504098A Pending JPH08506796A (ja) 1991-08-15 1992-08-13 ペプチドグリカン単量体（ｐｇｍ），そのｎ−アシル誘導体及びその金属錯体の、生体における免疫抑制状態及び肝抑制状態を補正するための薬剤調製への使用

Country Status (10)

Country Link
EP (1) EP0600974A1 (fr)
JP (1) JPH08506796A (fr)
BG (1) BG98628A (fr)
CA (1) CA2115270A1 (fr)
CZ (1) CZ30194A3 (fr)
HR (1) HRP920488A2 (fr)
HU (1) HU9400420D0 (fr)
RU (1) RU94027699A (fr)
SK (1) SK17994A3 (fr)
WO (1) WO1993003746A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU45382B (en) * 1986-11-19 1992-05-28 Pliva Sour Zagreb Process for preparing complex of n-acethyl-glucosis-aminyl-n-acethyl-muramoil-l-alanyl-d-izoglutaminyl-(l)-mezodiaminopimelyl-(d-amid)-(l)-al
US4868155A (en) * 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
YU62689A (en) * 1989-03-27 1991-02-28 Pliva Pharm & Chem Works N-acyl derivatives of peptidoglican monomer, their pharmaceutically acceptable salts, process for preparing thereof and their use as immunity modulators and immunoadjuvant

Also Published As

Publication number Publication date
CZ30194A3 (en) 1994-06-15
CA2115270A1 (fr) 1993-03-04
HU9400420D0 (en) 1994-08-29
RU94027699A (ru) 1996-04-10
HRP920488A2 (en) 1994-08-31
BG98628A (en) 1995-06-30
EP0600974A1 (fr) 1994-06-15
WO1993003746A1 (fr) 1993-03-04
SK17994A3 (en) 1994-08-10

Similar Documents

Publication Publication Date Title
EP0167263B1 (fr) Matrices contenant des médicaments pour introduction dans des zones de lésions cellulaires
JP3623962B2 (ja) ヒドロキソコバラミンの鼻中投与用医薬組成物
AU2010241263B2 (en) Use of Growth Hormone Releasing Factor Analogs in Treating Patients Suffering from Wasting
JPS6226218A (ja) がん性腫瘍転移の治療剤
CZ4997A3 (en) Preparation for regulating immune functions and regulation method of immunity system disorders
CA2176298C (fr) Traitement a l'aide de fluoroquinolone, en dose unique elevee
JP2005527592A (ja) α−ケトアルカン酸または−エステルもしくは−アミドを用いる腸閉塞の処置方法
JP2006524227A5 (fr)
Park et al. Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat
EP1450850B1 (fr) Methode d'administration d'un peptide alpha 1 de la thymosine
JP4672257B2 (ja) エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用
JPH11505222A (ja) ２〜６時間の活性成分放出期間をもつ上皮小体ホルモンの医薬投与形態
JPH08506796A (ja) ペプチドグリカン単量体（ｐｇｍ），そのｎ−アシル誘導体及びその金属錯体の、生体における免疫抑制状態及び肝抑制状態を補正するための薬剤調製への使用
JP2007537280A (ja) 免疫調節性化合物を用いる呼吸器のウイルス感染の治療又は予防
US7906486B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
JPH11504011A (ja) 疼痛の治療方法
EP1099446B1 (fr) Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du récepteur NK-1 et un agent antidépressant ou anxiolitique
Hanssen et al. Extended Experience with Recombinant a-2b Interferon with OR Without Hepatic Artery Embolization in the Treatment OF Midgut Carcinoid Tumours A preliminary report
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
JPH11511479A (ja) １，２，４−ベンゾトリアジンオキシド製剤
KR880003973A (ko) 약리적 활성 화합물 및 용도
WHITE et al. Gallamine in anesthesia for patients with chronic renal failure undergoing bilateral nephrectomy
KR20090103656A (ko) 섬유근육통 치료제
Boughton Drug points: Cardiac side effects of pentamidine
Barrett et al. Drug points: Hypertension in association with buserelin